CADL on Nasdaq
Candel Therapeutics
Company in Auburndale, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with VivoSim Labs, INC., Instil Bio, Inc. or Zivo Bioscience, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
-27777.6%Operating margin4
-15035.2%Net margin4
0.0%Revenue growth, 20224
-39.4%Return on equity5
-$32.7MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development92¢$20.8M
- Interest8¢$1.7M
Out of $125.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $30.5M | $19.3M |
| General and administrative | $17.8M | $14.1M |
| Total operating expenses | $48.3M | $33.4M |
| Loss from operations | -$48.3M | -$33.4M |
| Grant income | $89.0K | |
| Interest income | $3.9M | $1.1M |
| Interest expense | -$2.1M | -$2.1M |
| Change in fair value of warrant liabilities | $8.2M | -$20.8M |
| Total other income (expense), net | $10.1M | -$21.8M |
| Net loss and comprehensive loss | -$38.2M | -$55.2M |
| Net loss per share - basic | -$0.72 | -$1.74 |
| Net loss per share - diluted | -$0.72 | -$1.74 |
| Weighted-average common shares outstanding, basic | 53.0M shares | 31.7M shares |
| Weighted-average common shares outstanding, diluted | 53.0M shares | 31.7M shares |
Every line of the balance sheet in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $119.7M | $102.7M | |
| Prepaid expenses and other current assets | $1.7M | $1.1M | |
| Total current assets | $121.4M | $103.8M | |
| Fixed assets, net | $1.6M | $2.2M | |
| Lease right of use assets | $1.7M | $542.0K | |
| Restricted cash | $416.0K | $266.0K | |
| Other assets | $87.0K | $63.0K | |
| Total assets | $125.2M | $106.9M | |
| Accounts payable | $1.1M | $237.0K | |
| Accrued expenses | $7.3M | $5.1M | |
| Current portion of term loans | $0 | $9.9M | |
| Current portion of lease liability | $445.0K | $566.0K | |
| Warrant liabilities | $0 | $21.7M | |
| Other current liabilities | $89.0K | $0 | |
| Total current liabilities | $9.0M | $37.5M | |
| Deferred revenue | $89.0K | $0 | |
| Term loans, net of current portion | $46.1M | $1.7M | |
| Other long-term debt | $1.0M | $870.0K | |
| Lease liability, net of current portion | $1.5M | $407.0K | |
| Warrant liabilities | $15.6M | $0 | |
| Total liabilities | $73.3M | $40.5M | |
| Common stock, $0.01 par value; 150,000,000 shares authorized at December 31, 2025 and 2024; 55,020,911 and 46,933,088 shares issued at December 31, 2025 and 2024, respectively; and 54,898,303 and 46,810,480 shares outstanding at December 31, 2025 and 2024, respectively. | $550.0K | $469.0K | |
| Treasury stock (at cost) | -$448.0K | -$448.0K | |
| Additional paid-in capital | $282.2M | $258.5M | |
| Accumulated deficit | -$230.4M | -$192.2M | |
| Total stockholders' equity | $51.9M | $66.3M | $12.7M |
| Total liabilities and stockholders' equity | $125.2M | $106.9M | |
| Preferred stock par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock, shares, issued | 55.0M shares | 46.9M shares | |
| Common stock, shares, outstanding | 54.9M shares | 46.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$38.2M | -$55.2M |
| Depreciation expense | $845.0K | $990.0K |
| Impairment of fixed assets | $90.0K | $41.0K |
| Loss on the sale and disposal of fixed assets | $306.0K | $0 |
| Non-cash stock compensation expense | $3.8M | $5.3M |
| Non-cash lease expense | $321.0K | $274.0K |
| Non-cash interest expense | $138.0K | $119.0K |
| Change in fair value of warrant liabilities | -$8.2M | $20.8M |
| Accretion of debt discount | $360.0K | $270.0K |
| Prepaid expenses and other current assets | -$508.0K | $234.0K |
| Other assets | -$24.0K | $53.0K |
| Accounts payable | $802.0K | -$185.0K |
| Accrued expenses | $2.3M | $757.0K |
| Deferred income | $178.0K | |
| Lease liability | -$509.0K | -$513.0K |
| Net cash used in operating activities | -$38.3M | -$27.0M |
| Purchase of fixed assets | -$587.0K | -$16.0K |
| Proceeds from the sale of fixed assets | $27.0K | |
| Net cash used in investing activities | -$560.0K | -$16.0K |
| Proceeds from term loan, net of issuance costs | $47.9M | |
| Proceeds from issuance of common stock in registered direct offering, net of issuance costs | $14.3M | |
| Proceeds from option exercises | $516.0K | $1.7M |
| Principal payments on term loan payable to a bank | -$11.7M | -$9.2M |
| Net cash provided by financing activities | $56.1M | $94.3M |
| Net increase in cash, cash equivalents and restricted cash | $17.2M | $67.2M |
| Cash paid for interest | $1.3M | $1.8M |
| Change in right of use asset and lease liability due to lease amendment | $1.4M | |
| Initial fair value of warrant liability in connection with debt financing | $2.1M | |
| Capital expenditures in accounts payable and accrued expenses | $132.0K | |
| Deferred offering issuance costs in accounts payable and accrued expenses | $93.0K |
Recent filings
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Sep 11, 20264
- Sep 10, 20268-K
- Sep 10, 20263
- Sep 10, 20264
- Sep 10, 2026144
- Sep 9, 20268-K
- Aug 19, 20264
- Aug 17, 2026144
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Jul 27, 2026SCHEDULE 13G
- Jul 8, 20263
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ30283508
- SEC EDGARCIK 1841387
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCandel Therapeutics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10